AX-2024-004732

Oxytocin · 2 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2405-U8504

PASSIDENTITY CONSISTENT

Report ID: AX-2024-004732
Compound: Oxytocin
Compound class: Hypothalamic and posterior-pituitary hormones
Supplier: Homopeptide — Hunan Aslsen Technology Co., Ltd.
Batch / lot: HOMO-2405-U8504
Declared label claim: 2mg
Laboratory: VendorInvestigate
Assay date: 31 Jul 2024
Submitted: 09 Aug 2024
Quarter: 2024-Q3
Submitter: er.adeyemi
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the hypothalamic and posterior-pituitary hormones class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 32 min gradient, 214 nm	99.93	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — open-chain (reduced disulfide, +2 Da)	0.05	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	1006.4365	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1006.4337	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-2.8	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.64	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.05	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.62	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.14	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 32 min gradient	8.51	min	8.41 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.20	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	61,900	—	≥ 20,000	PASS
Resolution to nearest impurity	vs open-chain (reduced disulfide, +2 Da)	3.96	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 32 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 61,900, and skew follows the reported asymmetry factor of 1.20. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.05 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Oxytocin — main peak	8.51	4,856,908	99.93	—
2	open-chain (reduced disulfide, +2 Da)	7.96	2,430	0.05	+2.016
3	oxytocin dimer (intermolecular disulfide)	10.84	972	0.02	+1004.421
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1006.4365 Da, computed from C43H66N12O12S2. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1006.4337 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	336.4861	336.4852	-0.0009	8.6
2+	504.2255	504.2241	-0.0014	58.3
1+	1007.4438	1007.4410	-0.0028	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence -0.03 pp vs batch median
Total impurities (% area)	not stated	0.07
Largest single impurity (% area)	not stated	0.05
Water (%)	4.7	5.64
Counter-ion (%)	3.4	6.05
Peptide content (%w/w)	91.3	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 6 d) → laboratory (courier, ambient, 12 d) → assay.
Assay date: 31 Jul 2024
Submitted to the index: 09 Aug 2024
Laboratory: VendorInvestigate, Riga, Latvia
Method basis: 32 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot HOMO-2405-U8504 n=2

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2024-004731	HOMO-2405-U8504	Medutest	2024-Q3	99.93	5.49	103.7	Supplier-supplied	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Oxytocin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041439	QYB	QYB-2601-V5169	Janoshik	2026-Q2	99.60	4.30	—	Supplier-supplied	0	PASS
AX-2026-041438	QYB	QYB-2601-V5169	Nordanalyt	2026-Q2	99.93	3.89	—	Supplier-supplied	0	PASS
AX-2025-020055	ERP	ERP-2503-A7432	Janoshik	2025-Q2	98.82	4.60	—	Supplier-supplied	1	MARGINAL
AX-2025-020052	ERP	ERP-2503-A7432	Janoshik	2025-Q2	99.41	5.45	—	Supplier-supplied	1	MARGINAL
AX-2025-020056	ERP	ERP-2503-A7432	Nordanalyt	2025-Q2	98.81	5.01	—	Supplier-supplied	1	MARGINAL
AX-2025-020054	ERP	ERP-2503-A7432	Janoshik	2025-Q2	98.72	4.96	—	Supplier-supplied	1	MARGINAL
AX-2025-020053	ERP	ERP-2503-A7432	Janoshik	2025-Q2	99.46	4.84	93.5	Supplier-supplied	1	MARGINAL
AX-2025-018994	FGP	FGP-2406-W1827	Janoshik	2024-Q4	99.55	4.26	—	Supplier-supplied	0	PASS

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042181	Ipamorelin	HOMO-2608-A9045	Janoshik	2026-Q3	99.78	4.79	—	Supplier-supplied	1	MARGINAL
AX-2026-042172	Semaglutide	HOMO-2604-X8921	Janoshik	2026-Q3	99.64	5.16	91.9	Supplier-supplied	1	MARGINAL
AX-2026-042278	SLU-PP-332	HOMO-2602-Y2822	Kestrel	2026-Q3	99.71	4.42	—	Supplier-supplied	0	PASS
AX-2026-042180	Ipamorelin	HOMO-2608-A9045	Janoshik	2026-Q3	99.39	4.74	105.5	Supplier-supplied	1	MARGINAL
AX-2026-042184	Ipamorelin	HOMO-2608-A9045	Kestrel	2026-Q3	99.27	4.79	103.2	Supplier-supplied	1	MARGINAL
AX-2026-042274	SLU-PP-332	HOMO-2602-Y2822	VendorInvestigate	2026-Q3	98.71	4.72	—	Laboratory-retained	0	PASS
AX-2026-042183	Ipamorelin	HOMO-2608-A9045	VendorInvestigate	2026-Q3	99.38	4.97	—	Buyer-sourced	1	MARGINAL
AX-2026-042194	Retatrutide	HOMO-2605-V9833	PeptideMeter	2026-Q3	98.90	4.07	98.8	Supplier-supplied	3	MARGINAL